News Features Year in Review: Low-Risk TAVR Trials Big in 2019, but QoL Data Impresses, Too Michael O'Riordan December 18, 2019
News Features EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online Michael O'Riordan December 12, 2019
News Features Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too Michael O'Riordan December 09, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019